Endo International | ENDP - Le Bénéfice D'Exploitation



Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.88B 156M 2026-09
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 51.84M 12M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Hikma Pharmaceutical USD 348M 161M 2025-12
Ligand Pharmaceuticals USD 54.53M 2.1M 2026-09
Merck USD 7.33B 6.49B 2026-09
Novartis USD 5.14B 392M 2026-09
Pacira USD 2.57B 2.56B 2026-09
Perrigo USD 27.2M 3.7M 2026-09
Pfizer USD 662M 5M 2026-09
Phibro Animal Health USD 54.99M 2.36M 2025-12
Supernus Pharmaceuticals USD -21.04M 14.21M 2026-06
Takeda JPY 205.32B 3.9B 2026-09
Teva Pharmaceutical Industries USD 1.19B 954M 2026-09
Xeris Pharmaceuticals USD 5.17M 2.74M 2026-06
Zoetis USD 1.03B 88M 2026-09